A generic insomnia drug, Zolpidem Sublingual tablets has been launche by the drug major Lupin in the US market with 180 days of marketing exclusivity.

GAVIS Pharmaceuticals’ Zolpidem Sublingual tablets has been launched by Lupin Pharmaceuticals after having received final approval from the United States Food and Drug Administration (FDA) as well as from the FTC with 180 days of exclusivity.

Read EquityPandit’s Nifty Pharma Outlook for this week